Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 19 Apr 2023
Importance of carbohydrate antigen (CA 19-9) and carcinoembryonic antigen (CEA) in the prognosis of patients with duodenal adenocarcinoma: a retrospective single-institution cohort study" has been published in a new study.
Read Full NewsIn children with difficult-to-treat glaucoma, a nonvalved implant yields sustained reductions in intraocular pressure and medication burden for up to 5 years.
A population-based study finds that children with spina bifida are more likely than their peers in the general population to develop chronic kidney disease and ESRD — and to do so at younger ages.
1.
The pandemic had little impact on mental health symptoms.
2.
Q&A: Researchers discuss identifying potential new protein targets for melanoma therapeutics
3.
ASCO Future Focus: Follicular Lymphoma: Future Focus from the American Society of Clinical Onology
4.
Smoker's Painless Skin Nodules Flag a Fatal Diagnosis
5.
In Hemophilia A and B, a Novel Monoclonal Antibody Reduces Bleeding.
1.
Adaptive Neoantigen Vaccines for Solid Tumor Therapy
2.
The Importance of Understanding Your D-Dimer Levels: A Comprehensive Guide
3.
Exploring the Benefits of Teclistamab for Treating Advanced Cancer
4.
Preventing Heparin Induced Thrombocytopenia: Tips for Successful Anticoagulation Therapy
5.
What You Need To Know About Trametinib: A Miracle Cancer Treatment?
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Guideline Recommendations of Lorlatinib as First-Line Treatment for ALK+ NSCLC
2.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part VI
3.
From Relapse to Remission Mapping the Treatment Journey in Adult R R B Cell ALL The Critical Goal of MRD
4.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VII
5.
EGFR Mutation Positive Non-Small Cell Lung Cancer- Case Discussion & Conclusion
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge